These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 1531153)

  • 1. Vancomycin and teicoplanin: something old, something new.
    Phillips G; Golledge CL
    Med J Aust; 1992 Jan; 156(1):53-7. PubMed ID: 1531153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Teicoplanin in perspective. A critical comparison with vancomycin.
    Janknegt R
    Pharm Weekbl Sci; 1991 Aug; 13(4):153-60. PubMed ID: 1834985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycopeptide resistance in coagulase-negative staphylococci.
    Biavasco F; Vignaroli C; Varaldo PE
    Eur J Clin Microbiol Infect Dis; 2000 Jun; 19(6):403-17. PubMed ID: 10947214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A closer look at vancomycin, teicoplanin, and antimicrobial resistance.
    Zeckel ML
    J Chemother; 1997 Oct; 9(5):311-31; discussion 332-5. PubMed ID: 9373787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Teicoplanin, vancomycin, rifampicin: in-vivo and in-vitro studies with Staphylococcus aureus.
    Carper HT; Sullivan GW; Mandell GL
    J Antimicrob Chemother; 1987 May; 19(5):659-62. PubMed ID: 2956229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of teicoplanin and vancomycin against gram-positive bacteria from human clinical and veterinary sources.
    Jensen KT; Schønheyder H; Pers C; Thomsen VF
    APMIS; 1992 Jun; 100(6):543-52. PubMed ID: 1535201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized study of vancomycin versus teicoplanin for the treatment of gram-positive bacterial infections in immunocompromised hosts.
    Van der Auwera P; Aoun M; Meunier F
    Antimicrob Agents Chemother; 1991 Mar; 35(3):451-7. PubMed ID: 1828134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the in-vitro activity of the glycopeptide antibiotic LY333328 in comparison with vancomycin and teicoplanin.
    Harland S; Tebbs SE; Elliott TS
    J Antimicrob Chemother; 1998 Feb; 41(2):273-6. PubMed ID: 9533471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The comparative efficacy and safety of teicoplanin and vancomycin.
    Wood MJ
    J Antimicrob Chemother; 1996 Feb; 37(2):209-22. PubMed ID: 8707731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multidrug-resistant gram-positive pathogens. An update on current microbiological patterns.
    Marchese A; Debbia EA; Bacca D; Balistreri G; Musolino B; Schito GC
    Drugs; 1997; 54 Suppl 6():11-20. PubMed ID: 9474477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infective endocarditis and glycopeptides.
    Pittet D; Harding I
    J Infect; 1998 Sep; 37(2):127-35. PubMed ID: 9821086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative in vitro activity of teicoplanin and vancomycin against United States teicoplanin clinical trial isolates of gram-positive cocci.
    Kenny MT; Dulworth JK; Brackman MA
    Diagn Microbiol Infect Dis; 1991; 14(1):29-31. PubMed ID: 1826479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis of an amphiphilic vancomycin aglycone derivative inspired by polymyxins: overcoming glycopeptide resistance in Gram-positive and Gram-negative bacteria in synergy with teicoplanin in vitro.
    Szűcs Z; Bereczki I; Fenyvesi F; Herczegh P; Ostorházi E; Borbás A
    Sci Rep; 2022 Dec; 12(1):20921. PubMed ID: 36463278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The invitro activity of teicoplanin and vancomycin against gram positive microorganisms (corrected)].
    Kayaokay Y; Hasçelik G; Gür D; Akalin E
    Mikrobiyol Bul; 1991 Oct; 25(4):321-5. PubMed ID: 1839050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Teicoplanin administration in patients experiencing reactions to vancomycin.
    Smith SR; Cheesbrough JS; Makris M; Davies JM
    J Antimicrob Chemother; 1989 May; 23(5):810-2. PubMed ID: 2527221
    [No Abstract]   [Full Text] [Related]  

  • 16. In vitro susceptibility of Staphylococci and Enterococci to vancomycin and teicoplanin.
    Guzek A; Korzeniewski K; Nitsch-Osuch A; Rybicki Z; Prokop E
    Adv Exp Med Biol; 2013; 788():125-32. PubMed ID: 23835969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Teicoplanin versus vancomycin for proven or suspected infection.
    Cavalcanti AB; Goncalves AR; Almeida CS; Bugano DD; Silva E
    Cochrane Database Syst Rev; 2010 Jun; (6):CD007022. PubMed ID: 20556772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the in vitro antibacterial activity of teicoplanin and vancomycin against gram-positive cocci.
    Ravizzola G; Pirali F; Foresti I; Turano A
    Drugs Exp Clin Res; 1987; 13(4):225-9. PubMed ID: 2957187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. European Glycopeptide Susceptibility Survey of gram-positive bacteria for 1995. European Glycopeptide Resistance Survey Study Group.
    Felmingham D; Brown DF; Soussy CJ
    Diagn Microbiol Infect Dis; 1998 Aug; 31(4):563-71. PubMed ID: 9764397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Teicoplanin: a new glycopeptide antibiotic complex.
    Babul N; Pasko M
    Drug Intell Clin Pharm; 1988 Mar; 22(3):218-26. PubMed ID: 2966729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.